Business Context and Reporting Period
This filing is a Form 10-Q for Brooks Automation, Inc. (the predecessor name of Azenta, Inc.), covering the three months ended December 31, 2011, the first quarter of fiscal 2012. The company provided automation, vacuum, instrumentation, service, and life-science solutions. Semiconductor capital equipment represented approximately 51% of revenue in the quarter.
Financial Results and Liquidity
| Metric | Q1 FY2012 | Q1 FY2011 |
|---|---|---|
| Total revenue | $120.2 million | $178.4 million |
| Gross profit | $40.4 million | $57.3 million |
| Gross margin | 33.6% | 32.1% |
| Operating income | $1.5 million | $23.7 million |
| Net income attributable to Brooks | $3.0 million | $23.5 million |
| Diluted EPS | $0.05 | $0.36 |
| Cash flow from operations | $5.1 million | $17.7 million |
| EBITDA | $8.3 million | $28.5 million |
| Adjusted EBITDA | $10.8 million | $29.9 million |
Operating margin was approximately 1.2%, compared with 13.3% in the prior-year quarter; net margin was approximately 2.5%, compared with 13.2%. Revenue comprised $97.1 million of products and $23.1 million of services.
At December 31, 2011, cash and cash equivalents were $49.2 million, and total marketable securities were $145.3 million, producing aggregate cash, cash equivalents, and marketable securities of approximately $194.5 million. Total liabilities were $107.1 million and the filing does not report outstanding debt. The company stated that it had adequate resources for planned working capital and capital expenditures for the next twelve months, subject to market conditions.
Material Changes Versus the Prior Comparable Period
- Revenue declined 33%, primarily because the Contract Manufacturing segment was sold in June 2011, reducing comparable revenue by $45.9 million, and semiconductor equipment demand declined, reducing revenue by approximately $26.7 million.
- Gross margin improved because the company added higher-margin life-science revenue and divested the lower-margin Contract Manufacturing business. This benefit was partly offset by excess and obsolete inventory charges and lower semiconductor production utilization.
- Brooks Product Solutions revenue declined 24% to $85.3 million, while Brooks Global Services revenue increased 8% to $22.1 million.
- Brooks Life Science Systems generated $12.8 million of revenue, primarily from the RTS and Nexus acquisitions completed in fiscal 2011.
- Research and development expense increased to $11.9 million from $8.9 million, and SG&A increased to $26.7 million from $24.5 million, mainly due to acquisitions and investment in new products and operating initiatives.
- Operating income and EBITDA fell sharply as a result of lower revenue, increased operating expenses, and reduced fixed-cost absorption.
- Operating cash flow declined to $5.1 million from $17.7 million. Cash declined $9.6 million during the quarter after the Celigo acquisition, capital expenditures, and a $5.2 million dividend payment.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that recent semiconductor capital equipment demand had improved and expected this improvement, together with continued life-science growth, to produce higher near-term revenue than the quarter's $120.2 million.
- Management expected income from the ULVAC Cryogenics joint venture to decrease in the near term because of slowing demand for its products.
- The company acquired the Celigo cell cytometer product line on December 30, 2011, for $8.7 million in cash plus a $0.5 million deferred payment. It also acquired primarily intangible assets from Intevac for $3.0 million on January 6, 2012, and expected to expense a considerable portion as in-process research and development in the following quarter.
- Restructuring charges were $0.2 million, related primarily to a limited workforce reduction in Brooks Product Solutions in response to weaker semiconductor demand.
- The company maintained a full valuation allowance on net deferred tax assets. It indicated that continued profitability could result in a significant non-cash tax benefit if the allowance were reduced. Unrecognized tax benefits could decline by approximately $3.6 million over the next twelve months, primarily from expiring statutes of limitations.
- A legal settlement involving a former executive and insurers was approved in February 2012. The company expected to receive approximately $3.5 million of net insurance proceeds, to be recorded as a reduction of SG&A in the quarter ending March 31, 2012.
- The company declared a subsequent quarterly dividend of $0.08 per share, payable March 30, 2012. Future dividends remained discretionary and could be reduced, delayed, or canceled during a severe semiconductor downturn.
- Key risks include semiconductor industry cyclicality, dependence on major customers, acquisition and integration risks, foreign currency exposure, marketable-security interest-rate risk, pension obligations, tax audits, and the possibility that additional financing may not be available on favorable terms.
Most Important Facts for Investors to Verify
- Whether the stated recovery in semiconductor equipment demand and growth in life-science revenue materialized in subsequent quarters.
- The sustainability of the improved consolidated gross margin after the Contract Manufacturing divestiture and the impact of inventory charges and purchase-accounting amortization.
- The operating performance and integration costs of RTS, Nexus, Celigo, and the subsequent Intevac asset acquisition.
- The conversion of reported earnings into operating cash flow and the effect of dividends, acquisitions, and capital expenditures on liquidity.
- The timing and accounting treatment of the approximately $3.5 million insurance recovery and any related legal costs.
- Changes in the deferred tax asset valuation allowance, unrecognized tax benefits, and tax-audit outcomes.
- Customer concentration and exposure to semiconductor capital-equipment cycles, including the reported 13% largest-customer concentration and 51% semiconductor revenue mix.